Acyl Glucuronides

Covalent Binding and Its Potential Relevance
  • Hildegard Spahn-Langguth
  • Monika Dahms
  • Andreas Hermening
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 387)

Abstract

In general, phase-II metabolites of drugs, such as sulfates, O- or N-glucuronides, were anticipated to be rapidly excreted into urine and bile without exhibiting significant biological/pharmacological activity. However, a few years ago various conjugates were proven to have considerable affinity to pharmacological receptors or to contribute to toxic effects. Today, it is largely accepted that they may be active and/or reactive [Kroemer and Klotz, 1992; Spahn-Langguth and Benet, 1992a, b].

Keywords

Human Serum Albumin Glucuronic Acid Covalent Binding Acyl Migration Clofibric Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amos HE, Wilson DV, Taussig MJ, Carlton SJ “Hypersensitivity reactions to acetylsalicylic acid” Clin Exp Immunol 8, 563–572(1971)PubMedGoogle Scholar
  2. Bakke OM, Wardell WM, Lasagna L “Drug discontinuations in the United Kingdom and the United States: 1964–1983” Clin Pharmacol Ther 35, 559–567 (1984)PubMedCrossRefGoogle Scholar
  3. Benet LZ, Spahn H “Acyl migration and covalent binding of drug glucuronides — potential toxicity mediators” In: Siest G, Magdalou J, Burchell B (eds) “Molecular and Cellular Aspects of Glucuronidation”, Colloques INSERM/John Libbey Eurotext, Vol. 173, London, 305-309 (1988).Google Scholar
  4. Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschler E, Lin ET “Prediction of covalent binding of acidic drugs in man” Life Sci 53, PL 141–146 (1993).CrossRefGoogle Scholar
  5. Benet LZ, Bisher A, Volland C, Spahn-Langguth H “The pharmaco-and toxicokinetics of reactive and active phase II metabolites” In: Crommelin DJA, Midha KK (eds.) “Topics in Pharmaceutical Sciences” Med Pharm Scientific Publishers, Stuttgart, 533–544 (1992).Google Scholar
  6. Blanckaert N, Compernolle F, Leroy P, Van Hautte R, Fevery J, Heirwegh KPM “The fate of bilirubin-IXα glucuronide in cholestasis and during storage in vitro” Biochem J 171, 203–214 (1978)PubMedGoogle Scholar
  7. Boudinot FD, Homon CA, Jusko WJ, Ruelius HW “Protein binding of oxazepam and its glucuronide conjugates to human serum albumin” Biochem Pharmacol 39, 2115–2121 (1985)CrossRefGoogle Scholar
  8. Bradow G, Khan L, Fenselau C “Studies of intramolecular rearrangements of acyl-linked glucuronides using salicylic acid, flufenamic acid, and (S)-and (R)-benoxaprofen and confirmation of isomerization in acyl-linked δ9-11-carboxytetrahydrocannabinol glucuronide” Chem Res Toxicol 2, 316–324 (1989)PubMedCrossRefGoogle Scholar
  9. van Breemen RB, Fenselau C “Acylation of albumin by 1-O-acyl glucuronides” Drug Metab Dispos 13, 318–320(1985)PubMedGoogle Scholar
  10. Dahms M, Spahn-Langgguth H “Acyl glucuronides as reactive intermediates: Detection of flunoxaprofen protein adducts in biological material” Naunyn Schmiedeberg’s Arch Pharmacol, Suppl. (1995).Google Scholar
  11. Dickinson RG, King AR “Studies on the reactivity of acyl glucuronides — V. Glucuronide-derived covalent binding of diflunisal to bladder tissue of rats and its modulation by urinary pH and β-glucuronidase” Biochem Pharmacol 46, 1175–1182 (1993)PubMedCrossRefGoogle Scholar
  12. Ding A, Ojingwa JC, McDonagh AF, Burlingame AL, Benet LZ “Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry” Proc Nat Acad Sci USA 90, 3797–3801 (1993)PubMedCrossRefGoogle Scholar
  13. Dubois N, Lapicque F, Maurice MH, Pritchard M, Fournel-Gigleux S, Magdalou J, Abiteboul M, Siest G, Netter P “In vitro irreversible binding of ketoprofen glucuronide to plasma proteins” Drug Metab Dispos 21, 617–623 (1993)PubMedGoogle Scholar
  14. Dudley KH “Commentary: Stereochemical formulas of β-D-glucuronides” Drug Metab Dispos 13, 524–528 (1985)PubMedGoogle Scholar
  15. el Mouelhi M, Ruelius HW, Fenselau C, Dulik DM “Species-dependent enantioselective glucuronidation of three 2-arylpropionic acids: naproxen, ibuprofen and benoxaprofen” Drug Metab Dispos 16, 627–634 (1988)Google Scholar
  16. el Mouelhi M, Schwenk M “Stereoselective glucuronidation of naproxen in isolated cells from liver, stomach, intestine, and colon of the guinea pig” Drug Metab Dispos 19, 844–845 (1991)Google Scholar
  17. Faed EM “Properties of acyl glucuronides: Implications for studies of the pharmacokinetics and metabolism of acidic drugs” Drug Metab Rev 15, 1213–1249(1984)PubMedCrossRefGoogle Scholar
  18. Fournel-Gigleux S, Hamar-Hansen C, Motassim N, Antoine B, Mothe O, Decolin D, Caldwell J, Siest G “Substrate-specificity and enantioselectivity of arylcarboxylic acid glucuronidation” Drug Metab Dispos 16, 627–634(1988)PubMedGoogle Scholar
  19. Gräfe AK “PK/PD Correlation model for the triglyceride-lowering effect of lipid-regulating agents and the effect of the patients’ age: Gemfibrozil and its metabolites” PhD Thesis, Johann Wolfgang Goethe-University, Frankfurt/M., 1994.Google Scholar
  20. Grubb N, Weil A, Caldwell J “Studies on the in vitro reactivity of clofibryl and fenofibryl glucuronides. Evidence for protein binding via a Schiff*s base mechanism” Pharmacology 46, 357–364 (1993)Google Scholar
  21. Gugler R, Kurten JW, Jensen CJ, Klehr U, Hartlapp J “Clofibrate disposition in renal failure and acute and chronic liver disease” Eur J Clin Pharmacol 230, 237–241 (1979)Google Scholar
  22. Hargus SJ, Martin BM, Pohl LR “Covalent modification of rat liver dipeptidyl peptidase IV by diclofenac metabolites” The Fifth International Symposium on Biological Reactive Intermediates, Munich, Jan 1995, Abstract Volume, p. 74 (1995).Google Scholar
  23. Hasegawa J, Smith PC, Benet LZ “Apparent intramolecular acyl migration of zomepirac glucuronide” Drug Metab Dispos 10, 469–473 (1982).PubMedGoogle Scholar
  24. Hayball PJ, Nation RL, Bochner F “Stereoselective interactions of ketoprofen glucuronides with human plasma protein and serum albumin” Biochem Pharmacol 44, 291–299 (1992)PubMedCrossRefGoogle Scholar
  25. Hayball PJ, Nation RL, Bochner F, Sansom LN, Ahern MJ. Smith MD “The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis” Br J clin Pharmac 31, 546–550 (1991)CrossRefGoogle Scholar
  26. Hermening A, Gräfe AK, Mayer S, Mutschier E, Spahn-Langguth H “Pharmacokinetics of fibrates and their acyl glucuronides: Inclusion of a reversible metabolic step and cvalent binding into kinetic modelling” Naunyn Schmiedeberg’s Arch Pharmacol, Suppl (1995).Google Scholar
  27. Iwakawa S, Suganuma T, Lee SF, Spahn H, Benet LY, Lin ET “Direct determination of diastereomeric carprofen glucuronides in human plasma and urine and preliminary measurements of stereoselective metabolic and renal elimination after oral administration of carprofen in man” Drug Metab Dispos 17, 474–480 (1989)Google Scholar
  28. Iwakawa S, Spahn H, Benet LZ, Lin ET “Stereoselective disposition of carprofen, flunoxaprofen, and naproxen in rats” Drug Metab Dispos 19, 853–857 (1991)PubMedGoogle Scholar
  29. Iwakawa S, Spahn H, Benet LZ, Lin ET “Carprofen glucuronides: Stereoselective degradation and interaction with human serum albumin” Pharmaceut Res 5 (Suppl), 5214 (1988)Google Scholar
  30. King AR, Dickinson RG “Studies on the reactivity of acyl glucuronides — IV. Covalent binding of diflunisal to tissues of the rat” Biochem Pharmacol 45, 10431047 (1993).CrossRefGoogle Scholar
  31. Kroemer HK, Klotz U “Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors” Clin Pharmacokinet 23, 292–310 (1992)PubMedCrossRefGoogle Scholar
  32. Mayer S, Spahn-Langguth H, Gikalov I, Mutschier E “Pharmacokinetics of beclobric acid enantiomers and their glucuronides after single and multiple p.o. dosage of rac-beclobrate” Arzneim Forsch/Drug Res 42-2, 1354–1358(1993).Google Scholar
  33. Mayer S, Mutschler E, Benet LY, Spahn-Langguth H “In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers” Chirality 5, 120–125 (1993)PubMedCrossRefGoogle Scholar
  34. McKinnon GE, Dickinson RG “Covalent binding of diflunisal and probenecid to plasma protein in humans: Persistence of the adducts in the circulation” Res Commun Chem Pathol Pharmacol 66, 339–354 (1989)PubMedGoogle Scholar
  35. Ojingwa J, Spahn-Langguth H, Benet LZ “Reversible binding of tolmetin, zomepirac and their glucuronide conjugates to human serum albumin” J Pharmacokin Biopharm 22, 19–40 (1994)CrossRefGoogle Scholar
  36. Ojingwa J, Spahn-Langguth H, Benet LZ “Irreversible binding of tolmetin to macromolecules via its glucuronide: Bindng to blood constituents, tissue homogenates and subcellular fractions in vitro” Xenobiotica 24, 495–506 (1994)PubMedCrossRefGoogle Scholar
  37. Ott RJ, Giacomini KM “Stereoselective transport of drugs across epithelia” In: Wainer IW (ed) “Drug stereochemistry: Analytical methods and pharmacology” Marcel Dekker Inc, New York, Basel, Hong Kong, 281–314(1993)Google Scholar
  38. Rowe BJ, Meffin PJ “Diisopropylfluorophosphate increases clofibric acid clearance: Supporting evidence for a futile cycle” J Pharmacol Exp Ther 230, 237–241 (1984)PubMedGoogle Scholar
  39. Rubin A, Warrick RL, Wolen SM, Chernish SM, Ridolfo AS, Gruber CM “Physiological disposition of fenoprofen in man. III. Metabolism and protein binding of fenoprofen” J Pharmacol Exp Ther 183, 449–457(1972)PubMedGoogle Scholar
  40. Sallustio BC, Knights KM, Roberts BJ, Zacest R “In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins” Biochem Pharmacol 42, 1421–1425 (1991)PubMedCrossRefGoogle Scholar
  41. Smith PC, Langendijk PNJ, Hasegawa J, Benet LZ “Effect of probenecid on the formation and elimination of acyl glucuronides: Studies with zomepirac” Clin Pharmacol Ther 38, 121–127 (1985)PubMedCrossRefGoogle Scholar
  42. Smith PC, Benet LZ “Characterization of the isomeric esters of zomepirac glucuronide by proton NMR” Drug Metab Dispos 14, 503–505 (1986)PubMedGoogle Scholar
  43. Smith PC, Benet LZ, McDonagh A “Covalent binding of zomepirac glucuronide to proteins: Evidence for a Schiff base mechanism” Drug Metab Dispos 18, 639–644 (1990a)PubMedGoogle Scholar
  44. Smith PC, McDonagh AF, Benet LZ “Irreversible binding of zomepirac to plasma protein in vitro and in vivo” J Clin Invest 77, 934–939 (1986)PubMedCrossRefGoogle Scholar
  45. Smith PC, McDonagh AF, Benet LZ “Effect of an esterase inhibitor on the disposition of zomepirac and its covalent binding to plasma proteins in the guinea pig” J Pharmacol Exp Ther 230, 218–224 (1990b)Google Scholar
  46. Smith PC, Song WQ, Rodriguez RJ “Covalent binding of etodolac acyl glucuronide to albumin in vitro” Drug Metab Dispos 20, 962–965 (1992)PubMedGoogle Scholar
  47. Spahn H, Iwakawa S, Lin ET, Benet LZ “Influence of probenecid on the urinary excretion rates of the diastereomeric benoxaprofen glucuronides” Eur J Drug Metab Pharmacokinet 12, 233–239 (1987)PubMedCrossRefGoogle Scholar
  48. Spahn H, Iwakawa S, Lin ET, Benet LZ “Procedures to properly characterize formation of acyl glucuronides: Studies with benoxaprofen” Pharm Res 6, 125–132 (1989)PubMedCrossRefGoogle Scholar
  49. Spahn H, Zia-Amirhosseini P, Näthke I, Mohri K, Benet LZ “Characterization of drug adducts — formed with proteins via acyl glucuronides — by electrophoresis and blotting” Pharm Res 7 (Suppl), S–257 (1990)CrossRefGoogle Scholar
  50. Spahn H, Spahn I, Benet LZ “Probenecid-induced changes in the clearance of carprofen enantiomers — A preliminary study” Clin Pharmacol Ther 45, 500–505 (1989)PubMedCrossRefGoogle Scholar
  51. Spahn-Langguth H, Benet LZ “Active and reactive phase-II metabolites: The glucuronides pathway” In: Crommelin DJA, Midha KK (eds.) “Topics in Pharmaceutical Sciences” Med Pharm Scientific Publishers, Stuttgart, 533–544 (1992a)Google Scholar
  52. Spahn-Langguth H, Benet LZ “Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism?” Drug Metab Rev 24, 5–48 (1992b)PubMedCrossRefGoogle Scholar
  53. Spahn-Langguth H, Zia-Amirhosseini P, Iwakawa S, Ojingwa J, Büschges R, Benet LZ “Aktive und reaktive Glucuronide: Reversible und irreversible Interaktionen mit Proteinen” In: Dengler HJ, Mutschier E (eds) Fremdstoffmetabolismus und Klinische Pharmakologie, Gustav Fischer Verlag, Stuttgart, 29–50(1994)Google Scholar
  54. Spahn-Langguth H, Gräfe AK, Mayer S, Büschges R, Benet LZ “Fibrates: The occurrence of active and reactive metabolites” In: Reid E, Hill HM, Wilson ID (eds) “Biofluid and tissue analysis for drugs including hyperlipidaemics.” Methodological Surveys in Bioanalysis of Drugs, Vol. 23, The Royal Society of Chemistry, Cambridge, 87–102 (1994)Google Scholar
  55. Stogniew M, Fenselau C “Electrophilic reactions of acyl-linked glucuronides: Formation of clofibrate mercapturate in humans” Drug Metab Dispos 10, 609–613 (1982)PubMedGoogle Scholar
  56. Wells DS, Janssen FW, Ruelius HW “Interactions between oxaprozin glucuronide and human serum albumin” Xenobiotica 17, 1437–1449 (1987)PubMedCrossRefGoogle Scholar
  57. Williams AM, Worrall S, DeJersey J, Dickinson RG “Studies on the reactivity of acyl glucuronides: Glucuronide-derived adducts of valproic acid and plasma proteins and anti-adduct antibodies in humans” Biochem Pharmacol 43, 745–755 (1992)PubMedCrossRefGoogle Scholar
  58. Vree TB, Hekster YA, Anderson PG “Contribution of the human kidney to the metabolic clearance of drugs” Ann Pharmacother 26, 1421–1428 (1992)PubMedGoogle Scholar
  59. Zia-Amirhosseini P “Hypersensitivity to nonsteroidal anti-inflammatory drugs: Exploration of a theory” Ph.D. Thesis, School of Pharmacy, University of California, San Francisco, 1994Google Scholar
  60. Zia-Amirhosseini P, Ojingwa J, Spahn-Langguth H, McDonagh AF, Benet LZ “Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing” Clin Pharmacol Ther 55, 21–27 (1994)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Hildegard Spahn-Langguth
    • 1
  • Monika Dahms
    • 1
  • Andreas Hermening
    • 1
  1. 1.Department of PharmacologyJohann Wolfgang Goethe-University Frankfurt/M. Biocenter NiederurselFrankfurt/MGermany

Personalised recommendations